An analysis of relapse rates and predictors of relapse in 2 randomized, placebo-controlled trials of desvenlafaxine for major depressive disorder
Incidence and timing of taper/posttherapy-Emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder